BRAF and non-small cell lung carcinoma: Additionally, as a consequence of the favorable results of a phase II, single-arm study in both pre-treated and treatment-naïve NSCLC patients harboring BRAF V600E mutations, the combination of dabrafenib plus trametinib, has become the standard of care for these patients [16,17,18].